Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

TargetingMETDysregulation in Cancer
Gonzalo Recondo, Jianwei Che, Pasi A. Jänne, et al.
Cancer Discovery (2020) Vol. 10, Iss. 7, pp. 922-934
Open Access | Times Cited: 159

Showing 1-25 of 159 citing articles:

Small molecule inhibitors targeting the cancers
Guihong Liu, Tao Chen, Xin Zhang, et al.
MedComm (2022) Vol. 3, Iss. 4
Open Access | Times Cited: 89
At the crossroads of immunotherapy for oncogene-addicted subsets of NSCLC
Itziar Otano, Álvaro C. Ucero, Jon Zugazagoitia, et al.
Nature Reviews Clinical Oncology (2023) Vol. 20, Iss. 3, pp. 143-159
Closed Access | Times Cited: 84
MET alterations in NSCLC—Current Perspectives and Future Challenges
Jordi Remón, Lizza E.L. Hendriks, Giannis Mountzios, et al.
Journal of Thoracic Oncology (2022) Vol. 18, Iss. 4, pp. 419-435
Open Access | Times Cited: 78
Targeting cytokine and chemokine signaling pathways for cancer therapy
Ming Yi, Tianye Li, Mengke Niu, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 60
Oncogenic alterations in advanced NSCLC: a molecular super-highway
Alex Friedlaender, M. Pérol, Giuseppe Luigi Banna, et al.
Biomarker Research (2024) Vol. 12, Iss. 1
Open Access | Times Cited: 39
Emerging Targeted Therapies in Non-Small-Cell Lung Cancer (NSCLC)
Syeda A. Mina, Mohamed Shanshal, Konstantinos Leventakos, et al.
Cancers (2025) Vol. 17, Iss. 3, pp. 353-353
Open Access | Times Cited: 2
Targeted Therapy in Advanced and Metastatic Non-Small Cell Lung Cancer. An Update on Treatment of the Most Important Actionable Oncogenic Driver Alterations
David König, Spasenija Savic Prince, Sacha I. Rothschild
Cancers (2021) Vol. 13, Iss. 4, pp. 804-804
Open Access | Times Cited: 95
MET-Targeted Therapies and Clinical Outcomes: A Systematic Literature Review
Yiting Dong, Jiachen Xu, Boyang Sun, et al.
Molecular Diagnosis & Therapy (2022) Vol. 26, Iss. 2, pp. 203-227
Open Access | Times Cited: 54
Targeted therapy for lung cancer: Beyond EGFR and ALK
Mercedes Herrera, Cristina Serrano‐Gómez, Helena Bote, et al.
Cancer (2023) Vol. 129, Iss. 12, pp. 1803-1820
Closed Access | Times Cited: 33
Targeting MET in NSCLC: An Ever-Expanding Territory
Ying Han, Yinghui Yu, Da Miao, et al.
JTO Clinical and Research Reports (2024) Vol. 5, Iss. 2, pp. 100630-100630
Open Access | Times Cited: 14
Screening Ultra-Large Encoded Compound Libraries Leads to Novel Protein–Ligand Interactions and High Selectivity
Gavin W. Collie, Matthew Clark, Anthony D. Keefe, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 2, pp. 864-884
Open Access | Times Cited: 14
Activating Point Mutations in the MET Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors
Federica Pecci, Seshiru Nakazawa, Biagio Ricciuti, et al.
Cancer Discovery (2024) Vol. 14, Iss. 8, pp. 1440-1456
Open Access | Times Cited: 14
Novel therapeutic strategies for rare mutations in non-small cell lung cancer
Qitao Gou, Qiheng Gou, Xiaochuan Gan, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 13
Small-molecule-based targeted therapy in liver cancer
Ming Yue, Yanqiu Gong, Xuewen Fu, et al.
Molecular Therapy (2024) Vol. 32, Iss. 10, pp. 3260-3287
Closed Access | Times Cited: 11
Aberrant MET Receptor Tyrosine Kinase Signaling in Glioblastoma: Targeted Therapy and Future Directions
Abdulhameed Al‐Ghabkari, Bruce Huang, Morag Park
Cells (2024) Vol. 13, Iss. 3, pp. 218-218
Open Access | Times Cited: 10
Unveiling the potential of isatin-grafted phenyl-1,2,3-triazole derivatives as dual VEGFR-2/STAT-3 inhibitors: Design, synthesis and biological assessments
Heba A. Elsebaie, Maha-Hamadien Abdulla, Zainab M. Elsayed, et al.
Bioorganic Chemistry (2024) Vol. 151, pp. 107626-107626
Closed Access | Times Cited: 9
Immunotherapy in Oncogene-Addicted NSCLC: Evidence and Therapeutic Approaches
Lorenzo Foffano, Elisa Bertoli, Martina Bortolot, et al.
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 2, pp. 583-583
Open Access | Times Cited: 1
Ensartinib for advanced or metastatic non-small-cell lung cancer with MET exon 14 skipping mutations (EMBRACE): a multi-center, single-arm, phase 2 trial
Yang Xia, Panwen Tian, Mo Zhou, et al.
EClinicalMedicine (2025) Vol. 81, pp. 103099-103099
Closed Access | Times Cited: 1
Almonertinib-induced interstitial lung disease in an NSCLC patient co-harboring EGFR Ex19del mutation and MET de novo amplification: a case report and literature review
Wenjing Yang, Lin Shi, Hao Wang, et al.
Frontiers in Oncology (2025) Vol. 15
Open Access | Times Cited: 1
A narrative review of MET inhibitors in non-small cell lung cancer with MET exon 14 skipping mutations
Mariacarmela Santarpía, Marco Massafra, Vittorio Gebbia, et al.
Translational Lung Cancer Research (2021) Vol. 10, Iss. 3, pp. 1536-1556
Open Access | Times Cited: 53
The novel role of circular RNA ST3GAL6 on blocking gastric cancer malignant behaviours through autophagy regulated by the FOXP2/MET/mTOR axis
Penghui Xu, Xing Zhang, Jiacheng Cao, et al.
Clinical and Translational Medicine (2022) Vol. 12, Iss. 1
Open Access | Times Cited: 33
Discovery of D6808, a Highly Selective and Potent Macrocyclic c-Met Inhibitor for Gastric Cancer Harboring MET Gene Alteration Treatment
Chaofan Wang, Jie Li, Lingzhi Qu, et al.
Journal of Medicinal Chemistry (2022) Vol. 65, Iss. 22, pp. 15140-15164
Closed Access | Times Cited: 31
Response and acquired resistance to MET inhibitors in de novo MET fusion-positive advanced non-small cell lung cancer
Jin U. Kang, Qiu‐Mei Deng, Weineng Feng, et al.
Lung Cancer (2023) Vol. 178, pp. 66-74
Closed Access | Times Cited: 22
Patient-derived exosomes facilitate therapeutic targeting of oncogenic MET in advanced gastric cancer
Sujin Hyung, Jihoon Ko, You Jeong Heo, et al.
Science Advances (2023) Vol. 9, Iss. 47
Open Access | Times Cited: 20
Discovery of novel exceptionally potent and orally active c-MET PROTACs for the treatment of tumors with MET alterations
Pengyun Li, Changkai Jia, Zhiya Fan, et al.
Acta Pharmaceutica Sinica B (2023) Vol. 13, Iss. 6, pp. 2715-2735
Open Access | Times Cited: 18
Page 1 - Next Page

Scroll to top